Institutional shares held 264 Million
2.08M calls
728K puts
Total value of holdings $51.6B
$406M calls
$142M puts
Market Cap $55.6B
285,195,008 Shares Out.
Institutional ownership 92.73%
# of Institutions 1,730


Latest Institutional Activity in BDX

Top Purchases

Q2 2025
Vanguard Group Inc Shares Held: 32.3M ($6.3B)
Q2 2025
Norges Bank Shares Held: 3.79M ($740M)
Q2 2025
T. Rowe Price Investment Management, Inc. Shares Held: 16.2M ($3.15B)
Q2 2025
First Eagle Investment Management, LLC Shares Held: 8.79M ($1.71B)
Q2 2025
Massachusetts Financial Services CO Shares Held: 8.51M ($1.66B)

Top Sells

Q2 2025
Morgan Stanley Shares Held: 3.99M ($778M)
Q2 2025
Generation Investment Management LLP Shares Held: 2.76M ($538M)
Q2 2025
Price T Rowe Associates Inc Shares Held: 8.88M ($1.73B)
Q2 2025
Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Shares Held: 571K ($111M)
Q2 2025
Vontobel Holding Ltd. Shares Held: 347K ($67.7M)

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.


Insider Transactions at BDX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
148K Shares
From 28 Insiders
Grant, award, or other acquisition 122K shares
Open market or private purchase 6.75K shares
Exercise of conversion of derivative security 19.8K shares
Sell / Disposition
71.4K Shares
From 19 Insiders
Open market or private sale 19.9K shares
Payment of exercise price or tax liability 36.8K shares
Sale (or disposition) back to the issuer 14.7K shares

Track Institutional and Insider Activities on BDX

Follow BECTON DICKINSON & CO and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BDX shares.

Notify only if

Insider Trading

Get notified when an Becton Dickinson & CO insider buys or sells BDX shares.

Notify only if

News

Receive news related to BECTON DICKINSON & CO

Track Activities on BDX